Metastatic breast cancer treatment with the combination of PCS6422 and capecitabine (NGC-Cap) may increase the cancer-killing ...
Advancements in understanding tumor biology, identifying predictive biomarkers, and developing targeted therapies have ...
MedPage Today on MSN
Blockbuster Drug Lands First-Line Indication for HER2-Positive Breast Cancer
The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line ...
Enhertu plus Perjeta is the first new first-line treatment for HER2-positive breast cancer in over a decade, approved by the ...
Overall, tucatinib add-on to first-line maintenance therapy for HER2-positive metastatic breast cancer delayed progression by ...
The current melanoma staging system does not always reflect actual survival outcomes. In some cases, patients with thick but ...
A pioneering strategy is set to revolutionise care for thousands of people living with metastatic cancer in Greater ...
Variance in incidence seen across cancer types, but consistently increased with later stage at initial diagnosis.
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY ® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult ...
A combination of the antibody-drug conjugate enfortumab vedotin (Padcev) and the PD-1 inhibitor pembrolizumab (Keytruda) ...
In this study, researchers aimed to determine whether ctDNA is detectable in other bodily fluids besides blood, and to characterize any ctDNA they were able to detect.
Men are more likely to be diagnosed with advanced melanoma compared with women, and have a greater risk for recurrence and mortality.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results